e-learning
resources
Munich 2014
Monday, 08.09.2014
Understanding the benefit of current personalised medicine platforms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The real challenges in next generation sequencing for solid tumors
Y. Altschuler (Jerusalem, Israel)
Source:
International Congress 2014 – Understanding the benefit of current personalised medicine platforms
Session:
Understanding the benefit of current personalised medicine platforms
Session type:
Symposium
Number:
2833
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Altschuler (Jerusalem, Israel). The real challenges in next generation sequencing for solid tumors. International Congress 2014 – Understanding the benefit of current personalised medicine platforms
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Very early detection of small clones harbouring EGFR mutations in NSCLC by 2nd generation sequencing
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011
Next-generation sequencing and assessment of tumour mutational burden: are these tools ready for clinical routine use?
Source: International Congress 2019 – Molecular profiling and personalised treatment concepts in advanced non-small cell lung cancer: pertinent clinical dilemmas
Year: 2019
Identification of pleural infection microbiological patterns by applying next generation sequencing and bioinformatics analysis
Source: Virtual Congress 2020 – Antibiotic therapy for pneumonia and pleural infections
Year: 2020
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications
Source: Eur Respir J 2009; 33: 489-506
Year: 2009
The EGFR mutation detection in NSCLC by Next Generation Sequencing (NGS): cons and pros
Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Year: 2019
A new integrated PCR and microarray lab-on-chip for rapid MDR tuberculosis diagnosis
Source: Annual Congress 2011 - Tuberculosis: from bench to bedside
Year: 2011
Comparative analysis of lung cancer driver mutations from FFPE samples and liquid biopsies by IonTorrent next generation sequencing
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Microfluidics and HPLC analyses of novel lung cancer genes identified by arbitrarily primed PCR
Source: Eur Respir J 2005; 26: Suppl. 49, 456s
Year: 2005
Combined simultaneous analysis of the automated cyto-morphology and I-FISH on the same cell, as a novel method to detect a small population of lung cancer cells
Source: Eur Respir J 2006; 28: Suppl. 50, 335s
Year: 2006
Defining lineage relationships of multiple lung tumors through shared large genomic rearrangements
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013
Second primary lung cancers developed following different system tumors
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
The challenges of coupling new diagnostics and treatment capacity at country level
Source: Annual Congress 2013 –PG7 Tuberculosis: innovations in clinical and public health management
Year: 2013
The detection of EGFR mutations in liquid biopsy by allele-specific qPCR – the comparative evaluation of two common diagnostic tests
Source: International Congress 2018 – Genetics in chronic pulmonary diseases
Year: 2018
Utilising data from single cell approaches to study existing and recently emerging lung diseases?
Source: Virtual Congress 2021 – Utilising data from single cell approaches to study existing and recently emerging lung diseases?
Year: 2021
Radiomics in lung cancer: progress and challenges
Source: Virtual Congress 2021 – Chinese programme 2021
Year: 2021
Applications of CRISPR technology to lung cancer research
Source: Eur Respir J, 59 (1) 2102610; 10.1183/13993003.02610-2021
Year: 2022
Treatment sequencing in NSCLC EGFR+ – real-world data
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Diagnostic utility of PNA-LNA PCR clamp method for detection of EGFR exon 19 deletions and exon 21 codon L858 mutations in NSCLC samples with low tumor cells content
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept